XML 62 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1

Condensed Consolidating financial statements (Tables)

6 Months Ended

Jun. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Condensed Consolidating Statements of Operations

Condensed Consolidating Statements of Operations

		DaVita Inc.				Guarantor subsidiaries				Non- Guarantor subsidiaries				Consolidating adjustments				Consolidated total
For The Three Months Ended June 30, 2018
Patient services revenues		$	—			$	1,831,545			$	936,646			$	(49,788	)		$	2,718,403
Provision for uncollectible accounts		—				(27,159		)		(22,247		)		—				(49,406		)
Net patient service revenues		—				1,804,386				914,399				(49,788		)		2,668,997
Other revenues		205,317				214,266				43,137				(244,764		)		217,956
Total net revenues		205,317				2,018,652				957,536				(294,552		)		2,886,953
Operating expenses and charges		145,649				1,850,377				747,287				(294,552		)		2,448,761
Operating income		59,668				168,275				210,249				—				438,192
Debt expense		(120,814		)		(52,363		)		(9,274		)		62,759				(119,692		)
Other income, net		105,344				2,856				4,440				(110,646		)		1,994
Income tax expense		13,257				40,019				30,592				—				83,868
Equity earnings in subsidiaries		236,335				192,356				—				(428,691		)		—
Net income from continuing operations		267,276				271,105				174,823				(476,578		)		236,626
Net (loss) income from discontinued operations, net of tax		—				(34,770		)		56,579				47,887				69,696
Net income		267,276				236,335				231,402				(428,691		)		306,322
Less: Net income attributable to noncontrolling interests		—				—				—				(39,046		)		(39,046		)
Net income attributable to DaVita Inc.		$	267,276			$	236,335			$	231,402			$	(467,737	)		$	267,276

						Guarantor subsidiaries				Non- Guarantor subsidiaries				Consolidating adjustments				Consolidated total
For The Three Months Ended June 30, 2017		DaVita Inc.
Patient service revenues		$	—			$	1,654,430			$	879,780			$	(39,601	)		$	2,494,609
Provision for uncollectible accounts		—				(72,845		)		(36,755		)		—				(109,600		)
Net patient service revenues		—				1,581,585				843,025				(39,601		)		2,385,009
Other revenues		193,585				305,319				15,835				(200,349		)		314,390
Total net revenues		193,585				1,886,904				858,860				(239,950		)		2,699,399
Operating expenses		138,104				1,682,483				727,566				(239,950		)		2,308,203
Operating income		55,481				204,421				131,294				—				391,196
Debt expense		(106,159		)		(48,117		)		(13,038		)		59,380				(107,934		)
Other income		102,299				1,369				5,997				(104,867		)		4,798
Income tax expense		20,528				71,299				10,088				—				101,915
Equity earnings in subsidiaries		95,908				85,549				—				(181,457		)		—
Net income from continuing operations		127,001				171,923				114,165				(226,944		)		186,145
Net (loss) income from discontinued operations, net of tax		—				(76,015		)		6,008				45,487				(24,520		)
Net income		127,001				95,908				120,173				(181,457		)		161,625
Less: Net income attributable to noncontrolling interests		—				—				—				(34,624		)		(34,624		)
Net income attributable to DaVita Inc.		$	127,001			$	95,908			$	120,173			$	(216,081	)		$	127,001

		DaVita Inc.				Guarantor subsidiaries				Non- Guarantor subsidiaries				Consolidating adjustments				Consolidated total
For The Six Months Ended June 30, 2018
Patient service revenues		$	—			$	3,621,733			$	1,785,047			$	(97,303	)		$	5,309,477
Provision for uncollectible accounts		—				(17,531		)		(6,330		)		—				(23,861		)
Net patient service revenues		—				3,604,202				1,778,717				(97,303		)		5,285,616
Other revenues		400,882				419,226				114,070				(483,397		)		450,781
Total net revenues		400,882				4,023,428				1,892,787				(580,700		)		5,736,397
Operating expenses		279,005				3,641,471				1,547,743				(580,700		)		4,887,519
Operating income		121,877				381,957				345,044				—				848,878
Debt expense		(235,148		)		(104,560		)		(16,649		)		123,149				(233,208		)
Other income		209,425				5,379				10,144				(218,372		)		6,576
Income tax expense		27,644				88,962				37,999				—				154,605
Equity earnings in subsidiaries		377,452				258,851				—				(636,303		)		—
Net income from continuing operations		445,962				452,665				300,540				(731,526		)		467,641
Net (loss) income from discontinued operations, net of tax		—				(75,213		)		43,900				95,223				63,910
Net income		445,962				377,452				344,440				(636,303		)		531,551
Less: Net income attributable to noncontrolling interests		—				—				—				(85,589		)		(85,589		)
Net income attributable to DaVita Inc.		$	445,962			$	377,452			$	344,440			$	(721,892	)		$	445,962

		DaVita Inc.				Guarantor subsidiaries				Non- Guarantor subsidiaries				Consolidating adjustments				Consolidated total
For The Six Months Ended June 30, 2017
Patient service revenues		$	—			$	3,185,156			$	1,809,011			$	(76,772	)		$	4,917,395
Provision for uncollectible accounts		—				(133,898		)		(82,760		)		—				(216,658		)
Net patient service revenues		—				3,051,258				1,726,251				(76,772		)		4,700,737
Other revenues		414,971				610,937				31,925				(427,920		)		629,913
Total net revenues		414,971				3,662,195				1,758,176				(504,692		)		5,330,650
Operating expenses		270,014				2,891,303				1,406,901				(504,692		)		4,063,526
Operating income		144,957				770,892				351,275				—				1,267,124
Debt expense		(208,823		)		(95,760		)		(25,270		)		117,522				(212,331		)
Other income		202,636				4,172				9,583				(207,607		)		8,784
Income tax expense		54,481				307,165				21,934				—				383,580
Equity earnings in subsidiaries		490,409				248,165				—				(738,574		)		—
Net income from continuing operations		574,698				620,304				313,654				(828,659		)		679,997
Net (loss) income from discontinued operations, net of tax		—				(129,895		)		21,723				90,085				(18,087		)
Net income		574,698				490,409				335,377				(738,574		)		661,910
Less: Net income attributable to noncontrolling interests		—				—				—				(87,212		)		(87,212		)
Net income attributable to DaVita Inc.		$	574,698			$	490,409			$	335,377			$	(825,786	)		$	574,698

Condensed Consolidating Statements of Income

		Consolidated Total				Physician Groups				Unrestricted Subsidiaries				Company and Restricted Subsidiaries(1)
For The Six Months Ended June 30, 2018
Patient service operating revenues		$	5,309,477			$	—			$	—			$	5,309,477
Provision for uncollectible accounts		(23,861		)		—				—				(23,861		)
Net patient service operating revenues		5,285,616				—				—				5,285,616
Other revenues		450,781				—				—				450,781
Total net operating revenues		5,736,397				—				—				5,736,397
Operating expenses		4,887,519				—				—				4,887,519
Operating income		848,878				—				—				848,878
Debt expense, including refinancing charges		(233,208		)		—				—				(233,208		)
Other income		6,576				—				—				6,576
Income tax expense		154,605				—				—				154,605
Net income from continuing operations		467,641				—				—				467,641
Net income from discontinued operations, net of tax		63,910				16,466				323				47,121
Net income		531,551				16,466				323				514,762
Less: Net income attributable to noncontrolling interests		(85,589		)		(8,544		)		—				(77,045		)
Net income attributable to DaVita Inc.		$	445,962			$	7,922			$	323			$	437,717

(1) After elimination of the unrestricted subsidiaries and the physician groups.

Condensed Consolidating Statements of Comprehensive Income

Condensed Consolidating Statements of Comprehensive Income

						Guarantor subsidiaries				Non- Guarantor subsidiaries				Consolidating adjustments				Consolidated total
For The Three Months Ended June 30, 2018		DaVita Inc.
Net income		$	267,276			$	236,335			$	231,402			$	(428,691	)		$	306,322
Other comprehensive income (loss)		1,269				—				(50,529		)		—				(49,260		)
Total comprehensive income		268,545				236,335				180,873				(428,691		)		257,062
Less: Comprehensive income attributable to noncontrolling interest		—				—				—				(39,046		)		(39,046		)
Comprehensive income attributable to DaVita Inc.		$	268,545			$	236,335			$	180,873			$	(467,737	)		$	218,016

						Guarantor subsidiaries				Non- Guarantor subsidiaries				Consolidating adjustments				Consolidated total
For The Three Months Ended June 30, 2017		DaVita Inc.
Net income		$	127,001			$	95,908			$	120,173			$	(181,457	)		$	161,625
Other comprehensive income		436				—				49,142				—				49,578
Total comprehensive income		127,437				95,908				169,315				(181,457		)		211,203
Less: Comprehensive income attributable to the noncontrolling interests		—				—				—				(34,624		)		(34,624		)
Comprehensive income attributable to DaVita Inc.		$	127,437			$	95,908			$	169,315			$	(216,081	)		$	176,579

Condensed Consolidating Statements of Comprehensive Income

		Consolidated Total				Physician Groups				Unrestricted Subsidiaries				Company and Restricted Subsidiaries(1)
For The Six Months Ended June 30, 2018
Net income		$	531,551			$	16,466			$	323			$	514,762
Other comprehensive loss		(26,792		)		—				—				(26,792		)
Total comprehensive income		504,759				16,466				323				487,970
Less: Comprehensive income attributable to the noncontrolling interests		(85,589		)		(8,544		)		—				(77,045		)
Comprehensive income attributable to DaVita Inc.		$	419,170			$	7,922			$	323			$	410,925

(1) After elimination of the unrestricted subsidiaries and the physician groups.

Condensed Consolidating Balance Sheets

Condensed Consolidating Balance Sheets

						Guarantor subsidiaries				Non- Guarantor subsidiaries				Consolidating adjustments				Consolidated total
As of June 30, 2018		DaVita Inc.
Cash and cash equivalents		$	193,991			$	—			$	195,273			$	—			$	389,264
Restricted cash and equivalents		1,004				11,367				78,513				—				90,884
Accounts receivable, net		—				1,274,067				568,041				—				1,842,108
Other current assets		37,185				547,928				124,912				—				710,025
Current assets held for sale		—				5,101,853				951,228				—				6,053,081
Total current assets		232,180				6,935,215				1,917,967				—				9,085,362
Property and equipment, net		441,159				1,553,931				1,234,008				—				3,229,098
Intangible assets, net		199				46,491				53,565				—				100,255
Investments in subsidiaries		10,304,847				3,163,787				—				(13,468,634		)		—
Intercompany receivables		3,579,186				—				1,386,117				(4,965,303		)		—
Other long-term assets and investments		54,077				68,922				219,291				—				342,290
Goodwill		—				4,767,041				1,911,518				—				6,678,559
Total assets		$	14,611,648			$	16,535,387			$	6,722,466			$	(18,433,937	)		$	19,435,564
Current liabilities		$	1,831,526			$	1,219,455			$	461,433			$	—			$	3,512,414
Current liabilities held for sale		—				734,745				536,619				—				1,271,364
Intercompany payables		—				3,548,086				1,417,217				(4,965,303		)		—
Long-term debt and other long-term liabilities		7,897,430				728,254				494,437				—				9,120,121
Noncontrolling interests subject to put provisions		603,508				—				—				443,650				1,047,158
Total DaVita Inc. shareholders' equity		4,279,184				10,304,847				3,163,787				(13,468,634		)		4,279,184
Noncontrolling interests not subject to put provisions		—				—				648,973				(443,650		)		205,323
Total equity		4,279,184				10,304,847				3,812,760				(13,912,284		)		4,484,507
Total liabilities and equity		$	14,611,648			$	16,535,387			$	6,722,466			$	(18,433,937	)		$	19,435,564

						Guarantor subsidiaries				Non- Guarantor subsidiaries				Consolidating adjustments				Consolidated total
As of December 31, 2017		DaVita Inc.
Cash and cash equivalents		$	149,305			$	—			$	358,929			$	—			$	508,234
Restricted cash and equivalents		1,002				9,384				300				—				10,686
Accounts receivable, net		—				1,208,715				506,035				—				1,714,750
Other current assets		67,025				595,066				86,955				—				749,046
Current assets held for sale		—				4,992,067				769,575				—				5,761,642
Total current assets		217,332				6,805,232				1,721,794				—				8,744,358
Property and equipment, net		408,010				1,560,390				1,180,813				—				3,149,213
Intangible assets, net		250				50,971				62,606				—				113,827
Investments in subsidiaries		10,009,874				3,085,722				—				(13,095,596		)		—
Intercompany receivables		3,677,947				—				1,313,213				(4,991,160		)		—
Other long-term assets and investments		47,297				68,344				214,875				—				330,516
Goodwill		—				4,732,320				1,877,959				—				6,610,279
Total assets		$	14,360,710			$	16,302,979			$	6,371,260			$	(18,086,756	)		$	18,948,193
Current liabilities		$	238,706			$	1,181,139			$	436,262			$	—			$	1,856,107
Current liabilities held for sale		—				739,294				445,776				—				1,185,070
Intercompany payables		—				3,690,042				1,301,118				(4,991,160		)		—
Long-term debt and other long-term liabilities		8,857,373				682,630				469,587				—				10,009,590
Noncontrolling interests subject to put provisions		574,602				—				—				436,758				1,011,360
Total DaVita Inc. shareholders' equity		4,690,029				10,009,874				3,085,722				(13,095,596		)		4,690,029
Noncontrolling interests not subject to put provisions		—				—				632,795				(436,758		)		196,037
Total equity		4,690,029				10,009,874				3,718,517				(13,532,354		)		4,886,066
Total liabilities and equity		$	14,360,710			$	16,302,979			$	6,371,260			$	(18,086,756	)		$	18,948,193

Condensed Consolidating Balance Sheets

		Consolidated Total				Physician Groups				Unrestricted Subsidiaries				Company and Restricted Subsidiaries(1)
As of June 30, 2018
Cash and cash equivalents		$	389,264			$	—			$	—			$	389,264
Restricted cash and equivalents		90,884				—				—				90,884
Accounts receivable, net		1,842,108				—				—				1,842,108
Other current assets		710,025				—				—				710,025
Current assets held for sale		6,053,081				524,595				3,056				5,525,430
Total current assets		9,085,362				524,595				3,056				8,557,711
Property and equipment, net		3,229,098				—				—				3,229,098
Amortizable intangibles, net		100,255				—				—				100,255
Other long-term assets		342,290				—				—				342,290
Goodwill		6,678,559				—				—				6,678,559
Total assets		$	19,435,564			$	524,595			$	3,056			$	18,907,913
Current liabilities		$	3,512,414			$	—			$	—			$	3,512,414
Current liabilities held for sale		1,271,364				334,091				—				937,273
Payables to parent		—				56,761				3,056				(59,817		)
Long-term debt and other long-term liabilities		9,120,121				—				—				9,120,121
Noncontrolling interests subject to put provisions		1,047,158				—				—				1,047,158
Total DaVita Inc. shareholders’ equity		4,279,184				133,743				—				4,145,441
Noncontrolling interests not subject to put provisions		205,323				—				—				205,323
Shareholders’ equity		4,484,507				133,743				—				4,350,764
Total liabilities and shareholder’s equity		$	19,435,564			$	524,595			$	3,056			$	18,907,913

(1) After elimination of the unrestricted subsidiaries and the physician groups.

Condensed Consolidating Statements of Cash Flows

Condensed Consolidating Statements of Cash Flows

						Guarantor subsidiaries				Non- Guarantor subsidiaries				Consolidating adjustments				Consolidated total
For The Six Months Ended June 30, 2018		DaVita Inc.
Cash flows from operating activities:
Net income		$	445,962			$	377,452			$	344,440			$	(636,303	)		$	531,551
Changes in operating assets and liabilities and non-cash items included in net income		(361,991		)		26,502				92,210				636,303				393,024
Net cash provided by operating activities		83,971				403,954				436,650				—				924,575
Cash flows from investing activities:
Additions of property and equipment		(77,169		)		(258,471		)		(138,337		)		—				(473,977		)
Acquisitions		—				(8,195		)		(81,270		)		—				(89,465		)
Proceeds from asset and business sales		—				28,546				87,695				—				116,241
Proceeds (purchases) from investment sales and other items, net		32,415				(8,257		)		(1,021		)		—				23,137
Net cash used in investing activities		(44,754		)		(246,377		)		(132,933		)		—				(424,064		)
Cash flows from financing activities:
Long-term debt and related financing costs, net		584,500				(5,429		)		(5,090		)		—				573,981
Intercompany borrowing (payments)		225,216				(130,553		)		(94,663		)		—				—
Other items		(804,245		)		(13,208		)		(62,437		)		—				(879,890		)
Net cash provided by (used in) financing activities		5,471				(149,190		)		(162,190		)		—				(305,909		)
Effect of exchange rate changes on cash, cash equivalents and restricted cash		—				—				(3,473		)		—				(3,473		)
Net increase in cash, cash equivalents and restricted cash		44,688				8,387				138,054				—				191,129
Less: Net increase in cash, cash equivalents and restricted cash from discontinued operations		—				6,404				223,497				—				229,901
Net increase (decrease) in cash, cash equivalents and restricted cash from continuing operations		44,688				1,983				(85,443		)		—				(38,772		)
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year		150,307				9,384				359,229				—				518,920
Cash, cash equivalents and restricted cash of continuing operations at end of the period		$	194,995			$	11,367			$	273,786			$	—			$	480,148

						Guarantor subsidiaries				Non- Guarantor subsidiaries				Consolidating adjustments				Consolidated total
For The Six Months Ended June 30, 2017		DaVita Inc.
Cash flows from operating activities:
Net income		$	574,698			$	490,409			$	335,377			$	(738,574	)		$	661,910
Changes in operating assets and liabilities and non-cash items included in net income		(429,399		)		37,851				6,121				738,574				353,147
Net cash provided by operating activities		145,299				528,260				341,498				—				1,015,057
Cash flows from investing activities:
Additions of property and equipment		(50,966		)		(182,494		)		(165,480		)		—				(398,940		)
Acquisitions		—				(538,450		)		(81,389		)		—				(619,839		)
Proceeds from asset and business sales, net of cash divested		—				70,127				109				—				70,236
Proceeds (purchases) from investment sales and other items, net		49,036				(2,933		)		50,833				—				96,936
Net cash used in investing activities		(1,930		)		(653,750		)		(195,927		)		—				(851,607		)
Cash flows from financing activities:
Long-term debt and related financing costs, net		(54,992		)		(6,893		)		(2,147		)		—				(64,032		)
Intercompany (payments) borrowing		(39,814		)		117,661				(77,847		)		—				—
Other items		(223,511		)		(1,432		)		(76,203		)		—				(301,146		)
Net cash (used in) provided by financing activities		(318,317		)		109,336				(156,197		)		—				(365,178		)
Effect of exchange rate changes on cash, cash equivalents and restricted cash		—				—				4,192				—				4,192
Net decrease in cash, cash equivalents and restricted cash		(174,948		)		(16,154		)		(6,434		)		—				(197,536		)
Less: Net (decrease) increase in cash, cash equivalents and restricted cash from discontinued operations		—				(16,194		)		48,914				—				32,720
Net (decrease) increase in cash, cash equivalents and restricted cash from continuing operations		(174,948		)		40				(55,348		)		—				(230,256		)
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year		549,921				8,687				124,855				—				683,463
Cash, cash equivalents and restricted cash of continuing operations at end of the period		$	374,973			$	8,727			$	69,507			$	—			$	453,207

Condensed Consolidating Statements of Cash Flows

		Consolidated Total				Physician Groups				Unrestricted Subsidiaries				Company and Restricted Subsidiaries(1)
For The Six Months Ended June 30, 2018
Cash flows from operating activities:
Net income		$	531,551			$	16,466			$	323			$	514,762
Changes in operating and intercompany assets and liabilities and non-cash items included in net income		393,024				101,201				(323		)		292,146
Net cash provided by (used in) operating activities		924,575				117,667				—				806,908
Cash flows from investing activities:
Additions of property and equipment		(473,977		)		(2,097		)		—				(471,880		)
Acquisitions		(89,465		)		—				—				(89,465		)
Proceeds from asset and business sales		116,241				—				—				116,241
Investments and other items		23,137				(1,021		)		—				24,158
Net cash used in investing activities		(424,064		)		(3,118		)		—				(420,946		)
Cash flows from financing activities:
Long-term debt		573,981				—				—				573,981
Intercompany		—				57,783				—				(57,783		)
Other items		(879,890		)		—				—				(879,890		)
Net cash (used in) provided by financing activities		(305,909		)		57,783				—				(363,692		)
Effect of exchange rate changes on cash, cash equivalents and restricted cash		(3,473		)		—				—				(3,473		)
Net increase in cash, cash equivalents and restricted cash		191,129				172,332				—				18,797
Less: Net increase in cash, cash equivalents and restricted cash from discontinued operations		229,901				172,332				—				57,569
Net decrease in cash, cash equivalents and restricted cash from continuing operations		(38,772		)		—				—				(38,772		)
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year		518,920				—				—				518,920
Cash, cash equivalents and restricted cash of continuing operations at end of the period		$	480,148			$	—			$	—			$	480,148

(1) After elimination of the unrestricted subsidiaries and the physician groups.

X

- Definition

Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 3
-Paragraph i
-Subsection 10

+ Details

Name:	srt_CondensedStatementOfComprehensiveIncomeTableTextBlock
Namespace Prefix:	srt_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 3
-Paragraph i
-Subsection 10

+ Details

Name:	srt_ScheduleOfCondensedBalanceSheetTableTextBlock
Namespace Prefix:	srt_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 3
-Paragraph i
-Subsection 10

+ Details

Name:	srt_ScheduleOfCondensedCashFlowStatementTableTextBlock
Namespace Prefix:	srt_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 3
-Paragraph i
-Subsection 10

+ Details

Name:	srt_ScheduleOfCondensedIncomeStatementTableTextBlock
Namespace Prefix:	srt_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration